News
BPTH
3.000
+10.70%
0.290
Bio Path Holdings Inc <BPTH.OQ> expected to post a loss of $4.54 a share - Earnings Preview
Bio Path Holdings Inc expected to post a loss of $4.54 a share - Earnings Preview. The one available analyst rating on the shares is "buy" for the company. Wall Street's median 12-month price target for the stock is $40.
Reuters · 10h ago
Weekly Report: what happened at BPTH last week (0429-0503)?
Weekly Report · 2d ago
Bio-Path Holdings Has Been Granted Israeli Patent Number 269608 Titled "COMPOSITIONS COMPRISING P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION FOR USE IN TREATING CANCER OR AUTOIMMUNE DISEASE"
Benzinga · 5d ago
Looking Into Bio-Path Hldgs's Recent Short Interest
Bio-Path Hldgs's short percent of float has fallen 4.27% since its last report. The company has 67 thousand shares sold short, which is 8.96% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 05/01 18:00
Weekly Report: what happened at BPTH last week (0422-0426)?
Weekly Report · 04/29 10:53
Bio-Path files to sell 484K shares of common stock for holders
Bio-Path files to sell 484K shares of common stock for holders Apr. 24, 2024 4:56 PM ET. Bio-Path Holdings, Inc. Filed a prospectus related to the resale of up to 483,750 shares of stock. This prospectus is not an offer to sell.
Seeking Alpha · 04/24 20:56
Bio-Path Holdings, Sunshine Biopharma, INVO Bioscience among healthcare movers
Seeking Alpha · 04/23 14:00
BUZZ-U.S. STOCKS ON THE MOVE-AZZ, Vanda Pharma, Matterport
U.S. Stocks rose on Monday in choppy trading. The Dow Jones Industrial Average was up 1.01% at 38,371.51. The top three S&P 500 percentage gainers were Ford Motor Co, Nvidia and Vanda Pharma. The market is looking ahead to major tech earnings and a key inflation print this week. AZZ, Vanda Pharmaceutical and Matterport are up on the day.
Reuters · 04/22 18:10
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Vaxxinity, Inc. (NASDAQ:VAXX) fell sharply during Monday's mid-day session. The company announced its intention to voluntarily delist and deregister its Class A common stock. Matterport, Inc., shares jumped 184% to $4.93.
Benzinga · 04/22 17:26
MRIN, WISA and SMFL among mid-day movers
On the Move MRIN, WISA and SMFL among mid-day movers in SA. Matterport, mF International and Edible Garden AG are among the Gainers. YY Group Holding Limited is one of the losers in SA's top 10 list of companies.
Seeking Alpha · 04/22 16:52
12 Health Care Stocks Moving In Monday's Intraday Session
NKGen Biotech (NASDAQ:NKGN) shares rose 33.8% to $1.48 during Monday's regular session. The company's, Q4 earnings came out 4 days ago. MSP Recovery shares rose 29.74% and Assure Hldgs stock increased by 24.31%. Losers include Vaxxinity, Ocean Biomedical and Telomir Pharmaceuticals.
Benzinga · 04/22 16:31
BUZZ-U.S. STOCKS ON THE MOVE-AZZ, Smartsheet, Zions Bancorporation
Wall Street's main indexes rose on Monday after steep losses in the previous session. The Dow Jones Industrial Average was up 0.31% at 38,103.16. The top three S&P 500 percentage gainers were Ford Motor Co, Nvidia and Zions Bancorporation. Major tech earnings and a key inflation print are on the agenda this week.
Reuters · 04/22 16:17
Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers
Healthcare On the Move: Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers. S&P 500 Health Care Sector +0.08% to 1620.1. Moolec Science SA, NKGen Biotech, ProKidney among top gainers.
Seeking Alpha · 04/22 14:01
SBFM, BPTH and INDO among pre-market losers
On the Move SBFM, BPTH and INDO among pre-market losers. Hepion Pharmaceuticals -38% initiates wind-down activities in Phase 2b ‘ASCEND-NASH’ trial. Terronera surpasses 50% construction completion.
Seeking Alpha · 04/22 12:23
Weekly Report: what happened at BPTH last week (0415-0419)?
Weekly Report · 04/22 10:45
BIO-PATH HOLDINGS, INC. ANNOUNCES CLOSING OF $1.2 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 04/19 16:14
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Wang & Lee Group, Inc. Rose sharply in today's pre-market trading after the company reported a year-over-year increase in FY23 financial results. Redwoods Acquisition Corp. Shares gained 141% to $17.83 in pre- market trading. Netflix Inc. Shares jumped around 32% on Thursday after reporting upbeat results for its first quarter.
Benzinga · 04/19 09:45
12 Health Care Stocks Moving In Thursday's After-Market Session
Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. Biora Therapeutics, Mustang Bio and China SXT Pharmaceuticals were among the top gainers. Virpax Pharmaceuticals stock decreased by 18.2% during the session.
Benzinga · 04/18 20:31
Bio-Path Shares Pare Gains on Registered Direct Offering News
Bio-Path Holdings shares pared their gains after a favorable update for a leukemia drug study. The company announced a $1.2 million registered direct offering. The stock more than doubled after the announcement, peaking at $7.67. Bio-Path agreed to sell 375,000 shares.
Dow Jones · 04/18 19:43
Bio-Path announces $1.2M registered direct offering priced at-the-market
Seeking Alpha · 04/18 18:28
More
Webull provides a variety of real-time BPTH stock news. You can receive the latest news about Bio-Path Hldgs Inc through multiple platforms. This information may help you make smarter investment decisions.
About BPTH
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.